Xenobiotics in Chemical Carcinogenesis: Translational Aspects in Toxicology covers the translational toxicology of xenobiotics substances in carcinogenesis by explaining the toxicokinetic and toxicodynamic, toxicogenomic, biotransformation, and resistance mechanisms in the human body. The book begins with a historical review and link to future prospects for chemical carcinogenesis. It discusses major environmental xenobiotics and their risks in inducing cancer, along with content on toxic xenobiotics and their routes of exposure in humans, the role of xenobiotic metabolism in carcinogenesis, and the toxicokinetic and toxicodynamic of xenobiotics in cancer development. Lastly, the book explores current achievements such as using toxicogenomics for predicting the carcinogenicity of xenobiotic substances and the challenges posed by carcinogenic xenobiotic substances when examining preventive methods, diagnosis, and the development of anticancer drugs for specific toxicants. Covers the exposure and transmission of various toxic xenobiotics substances, including nanomaterials, to humans and their interaction with specific tissues in precipitating the development of cancers - Unravels the toxicokinetic and toxicodynamic processes of toxic xenobiotics in bioaccumulation - Examines the genetic aberrations in cancer genomes by genetic-environmental interactions in carcinogenesis - Explains the biotransformation mechanisms of toxic xenobiotics by gut microbes in humans Takes a comprehensive approach on its coverage of toxic xenobiotic compounds and the mechanisms involved in the development of different cancers Xenobiotics in Chemical Carcinogenesis covers the translational toxicology of xenobiotics substances in carcinogenesis by explaining the toxicokinetic and toxicodynamic, toxicogenomic, biotransformation, and resistance mechanisms in human body. The book begins with a historical review and linking it to the future prospective of chemical carcinogenesis. The book discusses major environmental xenobiotics and their risks in inducing cancer. The book goes on to discuss toxic xenobiotics and their routes of exposure in humans, the role of xenobiotic metabolism in carcinogenesis, and the toxicokinetic and toxicodynamic of xenobiotics in cancer development. Lastly, Xenobiotics in Chemical Carcinogenesis explores current achievements like using toxicogenomics for predicting the carcinogenicity of xenobiotic substances and the challenges posed by carcinogenic xenobiotic substances when examining preventive methods, diagnosis, development of anticancer drugs for specific toxicants. Dr. Akhileshwar Kumar Srivastava works as a Research Associate (ICMR) at CSIR-Central Food Technological Research Institute, Mysore, India. In his 11 years of research, he has published more than 18 research articles in reputed international journals, along with 4 books and 11 book chapters. His research specialization is primarily in the area of pharmacognosy with genetics, metabolomics, bioinformatics, and molecular biology associated with targeting virulent factors of diseases. In addition, he has studied at Augusta University (formerly, Georgia Regents University) in Augusta, GA, USA, on a J-1 Exchange Scholar Visa and at Ben-Gurion University, Israel. He is also a life member fellow in the Indian Science Congress and the Agriculture, Nutrition and Health Academy, UK. Dr. Dhruv Kumar is a Senior Associate Professor at School of Health Sciences and Technology, UPES University, Dehradun, India and his current research is focused on autophagy, cancer cell metabolism, tumour microenvironment, exosomes, mutational heterogeneity, cancer prevention, drug designing, NGS and COVID-19. After completion of B.Sc. in Chemistry from Banaras Hindu University (BHU) and M.Sc. in Bioinformatics from University of Allahabad, India, he has completed his Ph.D. in Cellular, Molecular and Industrial Biology from the University of Bologna (UNIBO), under highly prestigious fellowship, Indo-Italian Government fellowship. After his Ph.D., he obtained Postdoctoral training at the University of Kansas Medical Center, USA. During his Postdoctoral training, he worked towards understanding the molecular mechanism(s) of autophagy regulation and apoptosis in cancer stem cells (prostate, pancreatic and breast), focusing on the metabolic cross-talk between the tumour microenvironment (cancer associated fibroblast (CAF)) and head and neck squamous cell carcinoma (HNSCC) via HGF/c-MET and bFGF/FGFR signalling pathways. He has also worked on structure based drug designing for several cancers, COVID-19, mutational heterogeneity in cancer. Currently, his lab is focusing on metabolic heterogeneity in solid tumours and structure based drug designing for cancer and COVID-19. He has published more than 100 research articles, reviews and book chapters in reputed journals. Dr. Divya Singh is presently working as a scientist in Central Sericultural Research and Training Institut